Repurposing Amiloride into Breast Cancer Drugs with a Dual-Targeting Mechanism

将阿米洛利重新用于具有双靶向机制的乳腺癌药物

• 批准号: nhmrc : 1100432
• 负责人: A/Pr Michael Kelso
• 金额: $ 41.91万
• 依托单位: University of Wollongong
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/repurposing-amiloride-breast-targeting-mechanism/662510
• 关键词: Repurposing; Amiloride; into; Breast; Cancer

This project aims to transform a diuretic drug (amiloride) into a breast cancer drug that acts via a novel molecular mechanism. The science of medicinal chemistry will be used to remove amiloride's diuretic effects whilst gaining potent dual-activity against two breast cancer targets, uPA and NHE1. Our study will validate a new pharmacological approach in cancer treatment and produce patented drugs suitable for development into first-in-class breast cancer drugs.

该项目旨在将利尿药（阿米洛利）转化为通过新的分子机制发挥作用的乳腺癌药物。药物化学的科学将用于消除阿米洛利的利尿作用，同时获得针对两个乳腺癌靶点uPA和NHE1的有效双重活性。我们的研究将验证一种新的癌症治疗药理学方法，并生产适合开发成一流乳腺癌药物的专利药物。